ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2020
Synthesis and biological evaluation of RGD conjugated with Ketoprofen/Naproxen and radiolabeled with [
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Oral nanoliposomes functionalized with cRGD and polydopamine for enhanced antimalarial efficacy of disulfide bond-modified dihydroartemisinin prodrug.Drug delivery · 2025Article
- Interpreting the function of cell penetrating peptide (RGD) in drug transport to the cell membrane: a computational approach.Scientific reports · 2024Article
- Synthesis, Radiolabeling, and Biodistribution Study of a Novel DOTA-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer.Pharmaceutics · 2024Article
- Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic.ACS pharmacology & translational science · 2024Review
- RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.Cancer medicine · 2024Review
- Smart Nanoparticle-Based Platforms for Regulating Tumor Microenvironment and Cancer Immunotherapy.Advanced healthcare materials · 2023Review
- Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer.Journal of clinical medicine · 2023Article
- Peptide-Drug Conjugates: A New Hope for Cancer Management.Molecules (Basel, Switzerland) · 2022Review
- A novel tetrapeptide for chelator-free radiolabeling in optimized preparation ofAmerican journal of nuclear medicine and molecular imaging · 2022Article
- Review
- Development of PET Radioligands Targeting COX-2 for Colorectal Cancer Staging, a Review ofFrontiers in medicine · 2021Review
- A New NT4 Peptide-Based Drug Delivery System for Cancer Treatment.Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntegrins are interesting targets in oncology. RGD sequence has high affinity for α
objectivesIn this study, RGD was conjugated to ketoprofen/Naproxen to selectively transfer these non-selective COX inhibitors into cancer cells.
methodsKeto/Nap-RGD-N4 peptides were synthesized based on solid phase fmoc peptide synthesis. Radiolabeling with [
resultsRadiolabeled compounds showed high affinity to cells expressing α
conclusionProvided that NSAID drugs are conjugated to RGD, there will be a selective delivery to target tissues as well as synergetic anti-tumor effects which reduce systemic doses and toxicity. Graphical abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.